Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERVANTES trial in intermediate-risk early-stage cervical cancer after radical surgery
2023-504973-19-01Phase 3Authorised
- Sponsor
- Central and Eastern European Gynecologic Oncology Group
- Start
- Sep 2023
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, open-label trial of carboplatin and cisplatin in Cervical Cancer (CC) (2 arms), sponsored by Central and Eastern European Gynecologic Oncology Group. Primary endpoint: Disease-free survival. Planned start Sep 2023; status: authorised.
02
Drugs
carboplatincisplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on 2023-504973-19-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504973-19-01.